NEWS

"img

The Sermonix Blog

Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations

Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and D538G tumors to the lungs and liver. Lasofoxifene, in combination with palbociclib, was more effective than fulvestrant + palbociclib at reducing primary tumor growth. Lasofoxifene + palbociclib [...]
Read more

Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer

CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like palbociclib, is a promising approach for the treatment of endocrine therapy resistant ER+ metastatic breast cancer patients (Abstract 1056). “Lasofoxifene is a legacy molecule originally developed for the treatment of osteoporosis and vaginal dryness,” noted Geoffrey L. Greene, PhD, Virginia and [...]
Read more

Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene

Designation allows for expedited development and review of lasofoxifene as a potential precision medicine treatment for women who have estrogen receptor-positive (ER+) metastatic breast cancer with an ESR1 mutation COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific [...]
Read more

Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting

Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib versus fulvestrant and palbociclib in animal models. COLUMBUS, Ohio (May 7, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that it will present a poster on the [...]
Read more

Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors

Richard U. DeSchutter, Michael A. Friedman and Stephen Rubino bring decades of diverse C-level experience to biopharmaceutical company conducting a Phase 2 clinical trial for the precision medicine treatment of metastatic breast cancer COLUMBUS, Ohio (April 23, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of [...]
Read more

Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment

COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer Dr. David Portman will present at the Boston Oncology Investor Conference. Dr. Portman will discuss the Phase 2 study of [...]
Read more

Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer

Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University of Chicago to study efficacy of lasofoxifene COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced it will present a [...]
Read more

Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo model, and oncologists’ perceptions of ESR1 mutations and biomarker testing. COLUMBUS, Ohio, Nov. 14, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately […]
Read more

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer

Linical Accelovance Group will serve as research partner for study that compares lasofoxifene to fulvestrant. COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the launch of a Phase 2 trial for the treatment of [...]
Read more

Sermonix Pharmaceuticals Announces Recent Closure of $4.2 Million Seed Preferred Equity Bridge to Fund Operations, Prepare for Phase II Breast Cancer Study

Biotechnology company will globally develop and commercialize drug for treatment of advanced metastatic breast cancer. COLUMBUS, OH–(Marketwired – Oct 31, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced its recent completion of a $4.2 million [...]
Read more